Agustin Melian Biography and Net Worth

Insider of AlloVir

Dr. Melian is AlloVir’s Chief Medical Officer & Head of Global Medical Sciences.
Prior to joining AlloVir, Dr. Melian was an SVP in both Global Clinical Development and Medical Sciences at Alexion Pharmaceuticals. During his tenure there, the company achieved record timelines across clinical development including Ultomiris (a >500 patients rare disease development program fully executed from Investigational New Drug (IND) application to filing in

Dr. Melian has a background in DNA transcription and repair. Prior to his industry work, he practiced medicine and conducted Basic Immunology Research at The Brigham and Women’s Hospital in Boston. Dr. Melian graduated cum laude with degrees in Molecular Biophysics and Biochemistry and in Medicine from Yale University.

What is Agustin Melian's net worth?: The estimated net worth of Agustin Melian is at least $120.02 thousand as of July 2nd, 2021. Dr. Melian owns 21,665 shares of AlloVir stock worth more than $120,024 as of December 5th. This net worth estimate does not reflect any other assets that Dr. Melian may own. Learn More about Agustin Melian's net worth.
How do I contact Agustin Melian?: The corporate mailing address for Dr. Melian and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on Agustin Melian's contact information.
Has Agustin Melian been buying or selling shares of AlloVir?: Agustin Melian has not been actively trading shares of AlloVir over the course of the past ninety days. Most recently, Agustin Melian sold 812 shares of the business's stock in a transaction on Monday, October 4th. The shares were sold at an average price of $549.93, for a transaction totalling $446,543.16. Learn More on Agustin Melian's trading history.
Who are AlloVir's active insiders?: AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.
Are insiders buying or selling shares of AlloVir?: In the last year, insiders at the sold shares 7 times. They sold a total of 1,197 shares worth more than $10,936.41. The most recent insider tranaction occured on March, 26th when CAO Brett R Hagen sold 907 shares worth more than $8,135.79. Insiders at AlloVir own 32.1% of the company. Learn More about insider trades at AlloVir.
Information on this page was last updated on 3/26/2025.

Agustin Melian Insider Trading History at AlloVir

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/4/2021	Sell	812	$549.93	$446,543.16
9/28/2021	Sell	163	$554.76	$90,425.88
9/15/2021	Sell	34	$552.69	$18,791.46
7/2/2021	Sell	808	$459.77	$371,494.16	21,665
4/5/2021	Sell	791	$549.47	$434,630.77
3/22/2021	Sell	163	$597.31	$97,361.53	22,457

Agustin Melian Buying and Selling Activity at AlloVir

AlloVir Company Overview

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Today's Range

Now: $5.54

$5.35

$5.60

50 Day Range

MA: $5.53

$4.38

$8.03

2 Week Range

Now: $5.54

$7.96

$24.15

Volume

147,463 shs

Average Volume

15,685 shs

Market Capitalization

$27.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63